DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,070.00
-20.00 (-0.39%)
At close: Jan 19, 2026
0.60%
Market Cap140.08B
Revenue (ttm)238.39B
Net Income (ttm)770.31M
Shares Out27.04M
EPS (ttm)28.46
PE Ratio181.99
Forward PEn/a
Dividend120.00 (2.37%)
Ex-Dividend DateDec 29, 2025
Volume138,353
Average Volume162,709
Open5,130.00
Previous Close5,090.00
Day's Range4,910.00 - 5,130.00
52-Week Range4,720.00 - 6,390.00
Beta0.52
RSI44.80
Earnings DateMar 19, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 404
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.

Financial Statements